Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,864 matching trials from the live ClinicalTrials.gov search.

Filters: Minneapolis, Minnesota Clear all

Conditions: Prostate Cancer Metastatic
Interventions: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 48
States / cities: Orange, California • Palo Alto, California • Riverside, California + 41 more

Conditions: Pain
Interventions: Bupivacaine, Placebo; Drug
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: Up to 17 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Darusentan, Guanfacine, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 849 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 87
States / cities: Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more

Conditions: Acute Coronary Syndrome
Interventions: Dalcetrapib, Placebo; Drug
Lead sponsor: DalCor Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 186
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more

Conditions: Lung Cancer
Interventions: conventional surgery; Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 70
States / cities: Mobile, Alabama • Los Angeles, California • Orange, California + 49 more

Conditions: Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Juven, Non-Juven Supplement; Dietary Supplement
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 17 Years to 120 Years
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 230
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 181 more

Conditions: Late-onset Pompe Disease
Interventions: Not listed
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 17
States / cities: Irvine, California • Gainesville, Florida • Decatur, Georgia + 14 more

Conditions: Stargardt's Macular Dystrophy
Interventions: avacincaptad pegol, Sham; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more

Conditions: Generalized Myasthenia Gravis
Interventions: Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Matching Placebo SC, Batoclimab 340 mg SC bi-weekly; Drug
Lead sponsor: Immunovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Carlsbad, California + 27 more

Conditions: Heart Failure
Interventions: BNP; Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,361 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Eden Prairie, Minnesota • Minneapolis, Minnesota

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Binge Eating Disorder
Interventions: Integrative Cognitive-Affective Therapy, CBT-Guided Self Help; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Fargo, North Dakota

Conditions: Tachyarrhythmia
Interventions: defibrillation lead; Device
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 64
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 56 more

Conditions: Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
Interventions: Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 927 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 22
States / cities: Springdale, Arkansas • Beverly Hills, California • Glendale, California + 19 more

Conditions: Glioblastoma
Interventions: Treatment with hP1A8; Drug
Lead sponsor: OX2 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Osteosarcoma
Interventions: Biospecimen Collection, Laboratory Biomarker Analysis, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more

Conditions: Cutaneous Fistula
Interventions: Fistula Pouching System; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Hartford, Connecticut • Clearwarter, Florida • Edina, Minnesota + 3 more

Conditions: Fall, Fall Injury, Peripheral Artery Disease, Peripheral Arterial Disease
Interventions: Adapted Otago Exercise Program (OEP); Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Stage IV Osteosarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7
Interventions: Denosumab, Laboratory Biomarker Analysis, Pharmacological Study; Biological · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 11 Years to 49 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 132
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 104 more

Conditions: Pregnancy, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turners Syndrome
Interventions: Not listed
Lead sponsor: Verinata Health, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 26
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois + 22 more

Conditions: Pancreas Cancer
Interventions: PhiP; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Becker Muscular Dystrophy
Interventions: Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 12 Years to 50 Years · Male only
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 26
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more

Conditions: Transplant
Interventions: OCS Heart System; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 27
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more

Conditions: Schizophrenia
Interventions: Cognitive Remediation; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Granada Hills, California • Orange, California • New Haven, Connecticut + 11 more

Search by objective public record fields.

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer

STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

Access BNP Clinical Performance Evaluation: Testing and Clinical Concordance Study

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

Integrative Cognitive-Affective Therapy for Binge Eating Disorder

Lead Evaluation for Defibrillation and Reliability Post Approval Study

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

Feasibility Study of a New Fistula Pouching System

Integrating Fall Prevention Balance Exercises Into a Program for Older Adults With Peripheral Artery Disease (PAD): A Mixed Methods Feasibility Study

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Comparison of Aneuploidy Risk Evaluations

The Role of Meat-borne Carcinogens in Pancreatic Cancer

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

OCS Heart Perfusion Post-Approval Registry

Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone